在治疗症状性阻塞性多功能心肌病方面,Aficamten的效果优于β- 阻塞剂,结果更好,副作用更少. Aficamten outperforms beta-blockers in treating symptomatic obstructive hypertrophic cardiomyopathy, with better results and fewer side effects.

Aficamten, 心肌膜炎抑制剂, 显示出作为第一线治疗的强烈希望, 根据第三阶段试验数据, 治疗症状阻塞性超强的心血管病, 优于传统的乙型阻塞剂, 减少流出道梯度, 改善症状。 Aficamten, a cardiac myosin inhibitor, shows strong promise as a first-line treatment for symptomatic obstructive hypertrophic cardiomyopathy, outperforming traditional beta-blockers in reducing outflow tract gradients and improving symptoms, according to phase 3 trial data. 虽然没有直接对头试验,但MAPLE-HCM和其他研究的证据支持其有效性和安全性,副作用较少,风险管理计划比其他肌肉酶抑制剂简单. While no direct head-to-head trials exist, evidence from the MAPLE-HCM and other studies supports its efficacy and safety, with fewer side effects and a simpler risk management plan than other myosin inhibitors. 尽管如此,保险方面的障碍往往要求病人首先尝试较老的治疗方法。 Despite this, insurance hurdles often require patients to try older therapies first. 这一转变反映出越来越多的共识,即在阻塞性HCM的治疗中,应该考虑使用肌酸酶抑制剂,尽管它们不能替代其他疾病如心房动的β-阻塞剂. The shift reflects a growing consensus that myosin inhibitors should be considered earlier in treatment for obstructed HCM, though they do not replace beta-blockers for other conditions like atrial fibrillation.